Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 7 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Daewoong Pharmaceutical Co. Ltd. currently has 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 10 pending office actions are assigned to 10 distinct examiners, meaning that every application is being reviewed by a different individual. The prosecution is distributed across 7 distinct art units, a number that is lower than the count of distinct examiners. YONG SOO CHONG is the busiest examiner, currently responsible for 1 busiest examiner pending office action.
The fact that there are 10 distinct examiners for 10 pending office actions indicates that no examiner is handling more than one case. However, because these cases are situated within 7 distinct art units, some administrative overlap exists where multiple examiners are working within the same art unit. This distribution requires the applicant to manage 10 different examiner relationships while navigating the specific technical standards of 7 distinct art units. The Biotechnology & Pharmaceuticals technology area encompasses all of these active matters. Practitioners should note that the busiest examiner, YONG SOO CHONG, only oversees 1 busiest examiner pending office action.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §112 only | 2 (18%) |
| Double-patenting + other | 3 (27%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHONG, YONG SOO | 1 | 43.8% | +41.8% |
| COLEMAN, BRENDA LIBBY | 1 | 74.8% | +15.7% |
| SCHACHERMEYER, SAMANTHA LYNN | 1 | 35.7% | +70.8% |
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
| BORI, IBRAHIM D | 1 | 43.9% | +39.0% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
| SZNAIDMAN, MARCOS L | 1 | 37.4% | +16.1% |
| HIBSHMAN, SARAH GRACE | 1 | 38.2% | +40.7% |
| CHENG, KAREN | 1 | 76.4% | +26.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 5d |
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 21d |
| 18728531 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | REDWOOD, CHRISTOPHER EVAN | — |
| 18719016 | Dosage Regimen for Fexuprazan Injection Composition | BORI, IBRAHIM D | — |
| 17434388 | COMPOSITION COMPRISING ALBUMIN-COUPLED SLIT3 LRRD2 FOR PREVENTION OR TREATMENT OF MUSCLE DISEASE | REYNOLDS, FRED H | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 79d overdue |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 5d |
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 21d |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 26d |
| 18866386 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG, YONG SOO | — |
| 18859206 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | COLEMAN, BRENDA LIBBY | — |
| 18730278 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING OBESITY IN CANINE ANIMALS | SCHACHERMEYER, SAMANTHA LYNN | — |
| 18719016 | Dosage Regimen for Fexuprazan Injection Composition | BORI, IBRAHIM D | — |
| Art Unit | Apps |
|---|---|
| 1629 | 3 |
| 1623 | 2 |
| 1693 | 2 |
| 1622 | 1 |
| 1625 | 1 |
| 1628 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866386 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG, YONG SOO | 1623 | §112 | Non-Final OA | — | Pending | Nov 15, 2024 |
| 18859206 | POTASSIUM-COMPETITIVE ACID BLOCKERS FOR THE TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS | COLEMAN, BRENDA LIBBY | 1629 | §112 | Non-Final OA | — | Pending | Oct 23, 2024 |
| 18730278 | PHARMACEUTICAL COMPOSITION COMPRISING ENAVOGLIFLOZIN FOR PREVENTING OR TREATING OBESITY IN CANINE ANIMALS | SCHACHERMEYER, SAMANTHA LYNN | 1693 | §103 | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18728531 | METHOD FOR PRODUCING INTERMEDIATE USEFUL FOR SYNETHESIS OF SGLT INHIBITOR | REDWOOD, CHRISTOPHER EVAN | 1629 | §102§103§112DP | Non-Final OA | — | Pending | Jul 12, 2024 |
| 18719016 | Dosage Regimen for Fexuprazan Injection Composition | BORI, IBRAHIM D | 1629 | §103§112 | Final Rejection | — | Pending | Jun 12, 2024 |
| 18718904 | NOVEL ACID ADDITION SALT AND CRYSTALLINE FORM OF (2R, 3S)-2-(3-(4,5-DICHLORO-1H-BENZO[d]IMIDAZOL-1-YL)PROPYL)PIPERIDIN-3-OL | WELLS, LAUREN QUINLAN | 1622 | §103§112DP | Non-Final OA | — | Pending | Jun 12, 2024 |
| 18577071 | Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis | KOSAR, ANDREW D | 1625 | §102§103§112Other | Non-Final OA | 21d | Pending | Jan 05, 2024 |
| 18560968 | NEW FORMULATION FOR INJECTION COMPRISING 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE | SZNAIDMAN, MARCOS L | 1628 | §103DP | Final Rejection | 26d | Pending | Nov 15, 2023 |
| 17774888 | Liquid Pharmaceutical Composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N-methylmethanamine | HIBSHMAN, SARAH GRACE | 1693 | §103§112Other | Non-Final OA | 5d | Pending | May 06, 2022 |
| 17610303 | PREPARATION FOR PERCUTANEOUS ABSORPTION COMPRISING HIGH DOSE OF DONEPEZIL OR SALT THEREOF | CHENG, KAREN | 1623 | §103 | Final Rejection | 79d overdue | Pending | Nov 10, 2021 |
| 17434388 | COMPOSITION COMPRISING ALBUMIN-COUPLED SLIT3 LRRD2 FOR PREVENTION OR TREATMENT OF MUSCLE DISEASE | REYNOLDS, FRED H | 1658 | §103§112 | Non-Final OA | — | Pending | Aug 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDaewoong Pharmaceutical Co. Ltd. has 11 pending office actions as of October 2026, spread across 7 art units and 11 examiners.
Yong Soo Chong has the most, with 1 of Daewoong Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
